Introduction
The discovery and validation of protein biomarkers for the early detection of disease, for the assessment of a therapy's efficacy and side effects, and for drug development is one of the most active areas of proteomics research. Blood plasma represents a promising source of such markers as it has the advantage of being easily accessible. Plasma is circulating and exchanges analytes with cells and tissues within the entire body. In particular, proteins from dying cells and tumors that are shed, secreted or otherwise released into the blood stream are expected to provide a 'fingerprint' of the actual health status of the patient in general, and of specific organs in particular. However, the large volume of fluid accounts for a substantial dilution of the analytes secreted or shed by an organ or a tissue. Low concentrations, together with rapid clearance of some of the proteins create major challenges to a proteomics based biomarker discovery approach that remain unresolved in spite of recent advances of proteomics technology. More specifically, the detection and quantification of proteins in plasma at concentration in the ng/mL or sub ng/mL range, at which meaningful biomarkers can realistically be expected (1) has remained difficult.
Two types of approaches have been taken to detect plasma proteins at high sensitivity. In the first, ELISA or other immuno assays are developed to detect and quantify a specific target protein(s) in plasma samples. This approach has the advantage that the assay, once developed, can be applied to high numbers of samples with a high degree of robustness and at low cost. Such assays are sensitive, with limits of detection in the sub ng/mL range being routinely achieved. Unfortunately, the development of a reliable and sensitive immuno assay is slow and expensive. It has been estimated that the cost for the development of such an assay is in the order of one million US dollars. Therefore, immuno assays are most powerful for the routine testing of validated biomarkers in large numbers of samples or population screening but less suited for the discovery and validation of new markers.
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at Eth Bibliothek Zeitschri on August 13, 2007 www.mcponline.org The second type of approach is based on profiling plasma proteins by (quantitative) mass spectrometry. Typically, sets of plasma samples classified as healthy control or disease affected are analyzed and the results are compared for the detection of proteins with consistently increased or decreased abundance in the respective groups. While this approach is conceptually simple, its successful practical implementation has been exceedingly difficult, mainly for two reasons. The first is the complexity of the plasma proteome which is thought to contain tens of thousands of different proteins. If this proteome is digested with trypsin as it is required for most mass spectrometric methods, hundreds of thousands of peptides are generated. Such complexity clearly exceeds the peak capacity of any state-of-the-art LC-MS system, and low abundance components are masked by the (bio)chemical background. This can be overcome, at least to some extent, by extensive fractionation of the sample at the protein and/or peptide level and the sequential analysis of each fraction, a procedure that is costly and slow. The second reason is the limited dynamic range of mass spectrometers used for most proteomic studies (e.g. quadrupole / time-offlight, or ion trap instruments) which is typically three orders of magnitude. This is considerably less than the range of protein abundances in plasma which has been estimated to exceed ten orders of magnitude (2) . The nominal dynamic range of mass spectrometers can be further constrained by ion suppression effects, and if the analyses involve systematic (shotgun) tandem mass spectrometry of selected peptides, by under sampling (3) . As a consequence of these unresolved limitations, the many and diverse plasma proteome profiling approaches such as 2DE, SELDI-MS, or LC/LC-MS/MS have largely failed to detect proteins below the level of the most abundant plasma components. Recently, the use of most advanced mass spectrometers with high mass accuracy and high sensitivity in conjunction with extensive sample pre-fractionation have extended the sensitivity limit of detection of plasma protein profiles to the microgram/ml or ng/mL concentration range (4, 5, 6, 7) . However, the comparison of a single pair of samples using these methods consumed weeks of mass spectrometer and data processing time. Therefore, even though such profiling methods may reach impressive sensitivity levels, they are impractical for the routine quantitative analyses of larger numbers of clinical samples. Directed MS/MS strategies in which specific precursor ions are targeted for collision induced dissociation (CID) increase the sequencing efficiency (8) and potentially overcome some of the limitations of random precursor selection in data dependent approaches. They do not only allow sequencing of lower intensity signals, but they can also focus specifically on the peptides of interest (e.g.
peptides that exhibit differential expression) and can exclude peptides that have been previously observed. Nonetheless, such an approach does not provide precise quantification and still suffers from limited dynamic range and sensitivity. Recently, removal of the six most abundant proteins in plasma and analysis of the peptide tryptic digest by multiple reaction monitoring (MRM) has been proposed to increase the dynamic range for quantifying major plasma proteins (9) .
As an alternative to chromatographic or electrophoretic fractionation of the plasma proteome we recently introduced the selective isolation of the de-glycosylated forms of those peptides that are N-glycosylated in intact proteins (N-glycosites) by a solid-phase method, and their subsequent mass spectrometric analysis (10) . The method is based on the observation that most plasma proteins as well as proteins secreted or shed from cell surfaces are glycosylated (11) and that the selective analysis of N-glycosites leads to increased sensitivity due the dramatic reduction of the sample complexity (12) . In addition, it was shown that proteins originating from a range of tissues can be detected in plasma by this method (13) .
In the present study we applied a selective, highly sensitive quantitative mass spectrometry method for the targeted analysis of specific N-glycosites in samples isolated from plasma. To 1400 m/z in one sec). The combination of these factors accounts for a significant increase in sensitivity by several orders of magnitude compared to the limit of detection achieved in typical LC-MS experiment or even a product ion scan (14) .
In this study, we demonstrate that the application of MRM to N-glycosites isolated from plasma resulted in limit of detection of peptides in the low ng/mL to sub ng/mL range concentrations (15) . In addition, we also showed, using stable isotope labeled reference Table 1 . Concentrations of the synthetic peptide stock solutions were established by independent amino acid analysis. Generation and calibration of reference proteinTMEM27: Glycosylated humanTMEM27 protein (UniProt: Q9HBJ8) was generated by transiently transfecting HeLa cells with a TMEM27 full length construct (Invitrogen, Carlsbad CA). From a NP-40 insoluble fraction of these cells N-glycosites were isolated using the solid-phase isolation method described above. The concentration of TMEM27 in a cell extract was determined by multiple reaction monitoring using the isotopically labeled peptide (reduced and alkylated) as reference.
Aliquots of the HeLa cell extract containing TMEM27 was spiked into of human serum (Sigma) to reach a final concentration of TMEM27 ranging from 5 ng/mL to 750 ng/mL. After performing the glycocapture procedure, an aliquot corresponding to 4.3 microL of serum was analyzed by multiple reaction monitoring. Based on the spiked in heavy labeled peptide EATEISHVLLCDVTQR (8.6 fmol) the concentration of TMEM27 in the serum was determined.
Peptide separation: HPLC separations were performed either on a Dionex / LC Packings or Tempo TM Nano HPLC system (Applied Biosystems/MDS Sciex; Foster City, USA). A C18
capillary column with 75 micrometer inner diameter was used at a flow rate of 200 to 300 nL/min. A gradient from to 2% to 62% acetonitrile (containing 0.1% formic acid) over a 60 minute period was used.
Mass spectrometry:
The LC/MS and MS/MS analysis to characterize the N-glycosite samples were performed on hybrid linear ion trap FT-ICR instrument (Thermo, Bremen, Germany). Data were processed and visualized using in-house software (Pep3D) (18) . In parallel, peptide identification was performed on the linear ion trap instrument in data dependent mode (selection of the three most abundant peaks). The identification was performed using Bioworks (version 3.2.) using IPI human protein database. represented within the human proteome and characterized by the N-X-S or N-X-T sequence motif (X, being any amino acid except proline) (16, 17) . N-glycosites were prepared according to a solid-phase extraction protocol previously described (10) . A typical LC-MS map is shown in Figure 1 using the Pep3D visualization tool (18) . Table 1 . Each peptide selected as a reference for an MRM experiment was first validated to ensure that it fulfils the criteria of a proteotypic species (19), i.e. that it is observable (ionizes well and is within the practical mass range of the spectrometer), and unambiguously associated to a single protein (or closely related protein set).
The design of the reference peptides was important for the success of the MRM measurements. The incorporation of stable isotopes at or near the C-terminus ensured retention of the label in larger y-fragment ions of the reference peptide, thus facilitating precise quantification (20) . Non-degenerate fragments, i.e. ions with distinct masses, also minimized cross-talking between the MRM transitions of the internal standard and the endogenous analyte.
The synthetic reference peptides were also useful for confirming the identity of the target peptide through perfect co-elution and by exhibiting identical fragmentation patterns.
Specifically, the peptides showed the same MRM transitions and a constant ratio of the corresponding fragment ion signals across the entire elution profile. A minimum mass difference of six daltons was appropriate to properly separate the isotopes clusters of analyte and reference.
Optimization of MRM transitions:
The choice of the transitions is critical for the success of MRM experiments. Ideally, a large fraction of the precursor ions current should be converted into a few specific fragments which are indicative for the target peptide. Although the mass of peptide fragments are predictable, their observed intensities needed to be derived from empirical data, as algorithms that reliably predict fragmentation patterns are still lacking.
Therefore, the reference synthetic peptides were used to optimize the collision conditions.
Aliquots of the reference peptides were injected into the LC-MS/MS system and fragment ion spectra were recorded under different collision energies (ranging from 10 to 50 eV). Doubly or triply charged peptides were typically chosen to ensure proper separation by the first analyzer of the precursor of the co-eluting heavy labeled internal standards. Singly charged ions were disqualified due to their usually poor fragmentation. Higher charge state ions (four and higher) were excluded to avoid overlapping isotope clusters that may result in cross talk between the isotope cluster of the reference and endogenous peptides. Results from the MRM optimization are illustrated in Figure 2 for the peptide 1, where the relative abundance of the precursor ions and specific y-fragments were measured at various collision energies.
The voltage was considered optimal when a major part of the precursor ion was converted into high mass y-ions, while secondary (internal) fragments remained lowest. The optimized conditions for each peptide, as well as the chromatographic coordinates were recorded for use in the experiments described below.
Figure 2: MRM optimization

Detection limits of isotopically labeled peptides in N-glycosite samples isolated from plasma:
To assess the quantitative performance of the technique for specific peptides in a complex sample we used isotopically labeled peptides for which the MRM conditions had been optimized and determined their respective limits of detection and quantification (LOD and LOQ, respectively). Aliquots of four isotopically labeled synthetic peptides ( Table 1, peptides 1-4) were spiked into in N-glycosite samples that had been derived from human plasma. The peptide amounts added spanned a concentration range of five orders of magnitude (5 amol/uL to 500 fmol/uL). For each analyte (endogenous and reference peptides), the doubly charged precursor ion and two optimized MRM transitions were measured, corresponding to a total of 16 transitions (see Figure 3) . Each transition was monitored for 50 ms. Figure 4 shows the dilution curves for three representative transitions 526/609; 609/821, 444/ 502, corresponding to the peptides, LDVDQALDR, TM*FPDLTDVR, and DGTLVAFR, respectively. than the limit observed for the commonly used "full scan" LC-MS methods (21) .The achieved detection limit is also lower than the 0.5 microg/mL limits reported after affinity enrichment of selected peptides from whole plasma digests using the SISCAPA method or by analyzing plasma samples depeleted for the six highest abundance proteins (9) . This level of sensitivity was achievable because the number of transitions was limited, and thus a high duty cycle (approximately one to two seconds) and sufficient sampling time for each transition (typically 20 to 50 ms) could be obtained. While the conventional approaches were only able to analyze the classical plasma proteins, the MRM technique combined with a drastic reduction of the sample complexity lowers the limit of detection to a range that includes proteins originating from tissue leakage and the level of validated plasma biomarkers.
Detection limit for N-glycosylated protein spiked into human plasma.
While the detection limits achieved with isotopically labeled peptides spiked into N-glycosite
samples clearly demonstrated the advantages of combining MRM with the selective isolation of an information rich sub proteome, it is conceivable that some of these advantages would be mitigated by poor yields in the protocols used to isolate the N-glycosites. We therefore measured the limit of detection of a glycoprotein spiked at defined amounts into plasma samples.
To generate a reliable source of a protein modified with human glycan structure we expressed a glycosylated form of the recombinant protein TMEM27 in HeLa cells. The concentration of TMEM27 in a cell extract was determined by MRM (data not shown) using a synthetic isotopically labeled form of one proteotypic TMEM27 peptide as calibrant (EATEISHVLLC*DVTQR, with C*= carbamidomethyl; seeTable 1, peptide #5). Subsequently, this calibrated protein solution was spiked into human serum aliquots to reach a final TMEM27 concentration of 10 ng/mL . The combined sample was processed using the glycocapture protocol described above. Prior to LC-MS MRM analysis, the isotopically labeled TMEM27 reference peptide was spiked into the sample to a concentration corresponding to 50 ng/mL TMEM27 in serum. By MRM analysis the concentration of TMEM27 present in the N-glycosite fraction was determined to correlate to 5 ng/mL TMEM27 ( Figure 5 ) in serum, which translates in an overall recovery rate of 50%. The presence of endogenous TMEM27 in plasma sample used for this study could not be detected at concentration level above 2 ng/mL.To establish the robustness and the reproducibility of the entire analytical process four independent dilution series were performed in which variable amounts of recombinant TMEM27 protein ranging from 5 to 750 ng/mL were spiked into aliquots of the glycosite fraction). The samples were processed and measured independently.
The results of the MRM analyses are shown in Figure 6 and indicate excellent linearity in the range of concentrations measured, down to a limit in the low ng/mL range. The reproducibility of the entire process, as indicated by an average coefficient of variance (%CV) below 20 % (15% in most cases), is well within acceptance considering the multiple steps of the sample preparation (see Table 2 , supplementary material). These results indicate that the glycopeptide isolation procedure combined with MRM technology enables the highly reproducible isolation of glycosylated proteins from serum samples and the quantitative determination down to the low ng/ml concentration range. To determine the maximal number of transitions that could be measured in one single run without compromising the LOD, we systematically increased the number of transitions and related this number to the actual sensitivity. The data (not shown) indicated that 50 to 100
transitions with an overall duty cycle of some five seconds or less per full cycle yielded results without appreciable loss of sensitivity.
To further and significantly increase the total number of transitions that can be measured in a 
Conclusion
In this study we have demonstrated the performance of a platform integrating an effective reduction of sample complexity through selective isolation of N-glycosite peptides and a sensitive mass spectrometry technique, which enables precise quantification of peptides at very low concentrations in plasma. The reduction of sample complexity was essential to lessen the biochemical background in order to reach a low limit of detection. The recovery of the N-glycosite peptides was determined to be 50% in spite of the involved sample preparation protocol, as demonstrated by spiking known amounts of a specific protein into the plasma prior to its processing. Triple quadrupole (and triple quadrupole derived)
instruments allow the analysis of complex samples with high selectivity due to two levels of mass selection and the non-scanning nature of the technique enabled higher sensitivity and a wider dynamic range. It permits precise quantification when used in conjunction with stable isotope dilution using produce the antibodies and develop an essay). The actual rate limiting step is the synthesis of the isotopically labeled internal standards, which has become routine. The addition of internal standard at the beginning of the analysis would take into account losses which could occur during the entire sample preparation process. In that context, the approach using chimeric recombinant proteins that concatenate all the peptides to be quantified in a single construct (QconCAT) represents an attractive option (22) . An alternative strategy for future proteomic studies consists in hypothesis-driven screens of larger sets of peptides. In analogy to high throughput genomics screens, a two stage approach can be adopted: firstly, the creation of an inventory of all the elements present in a proteome (e.g. PeptideAtlas, (19) , and secondly screen for each element in numerous samples (in a way similar to arrays used for genomics studies). With an established catalog of peptides, the scheduled MRM technique can be used to detect and quantify targeted peptides (including low abundant components) to overcome the limitation of classical shotgun strategies. As comprehensive peptide and protein databases become available, hypothesis-driven mass spectrometric analyses combined with an effective sample preparation to drastically reduce complexity (and thus the chemical background) are likely to become more routine, as they enable detection of peptides at concentrations several orders of magnitude lower than current methods.
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